KRAS and spindle cell sarcoma: Herein, we report that the new inhibitor, CCT3833, mediated an unconfirmed partial response in a patient with aggressive KRAS-mutant spindle cell sarcoma who was not eligible for surgery or chemotherapy, and who did not respond to the multikinase inhibitor pazopanib.